Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

Starting soon

Conditions studied: Drug Resistant Epilepsy, Refractory Epilepsy

In brief

This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.

Key facts

Study ID

NCT07546253

Run by

NeuroOne Medical Technologies Corporation

People needed

100

Starts

2026-07-01

Expected to finish

2028-07-01

Last updated by the study team

2026-04-22

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with drug resistant epilepsy (DRE)
• Patients who have received or will receive EVO® sEEG-RF implants
• Patients who have undergone or may undergo an RF ablation procedure using the OneRF Ablation System.
• Patient, or legal guardian, understands study procedures and voluntarily signs informed consent in accordance with institutional policies. In the event that the patient is under the age of 18, the patient may also be required (per IRB) to sign an assent affirming their agreement to participate.

You may not qualify if…

• Any condition that, in the judgement of the clinician, would make the participant inappropriate for registry participation

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.